Dorothy M. Supp, Ph.D.

Research interests

Skin biology and wound healing: molecular biology of keloid and hypertrophic scars, including development of novel treatment and prevention strategies; organotypic in vitro and in vivo scar models; preclinical assessment of scar therapies, including compression and laser therapy; vitamin D and scar formation; eicosanoids and angiogenesis in wound healing

Tissue engineering and regenerative medicine: development of next-generation skin substitutes, including engineered skin with natural pigmentation, de novo hair follicle development, and neovasculogenesis; epidermal stem cell identification and propagation; cutaneous gene therapy for epidermolysis bullosa; organotypic models for melanoma research

Biography

Dr. Supp was born and raised in Yonkers, New York and attended Cornell University. She moved to Cincinnati, OH to pursue graduate studies in Developmental Biology at the University of Cincinnati and Cincinnati Children’s Hospital Research Foundation. Her research interests have been focused on wound healing since 1997 when she was awarded a research fellowship at the Cincinnati Shriners Burns Hospital. In 2000 she was awarded her first independent medical research grant from Shriners; since then, her research has been continuously supported by grant funding from the Shriners Hospitals for Children. She remains dedicated to the mission of the Shriners Hospitals and continues to pursue translational research aimed at improving the lives of children with burns, scars, and congenital skin diseases.

Education and training

  • S., Biology, Cornell University, Ithaca, NY
  • D., Developmental Biology, University of Cincinnati College of Medicine, Cincinnati, OH
  • Postdoctoral Fellowship, Perinatology, Children’s Hospital Research Foundation, Cincinnati, OH
  • Research Fellowship, Tissue Engineering, Shriners Hospitals for Children, Cincinnati, OH

Publications

Selected recent publications (past 5 years)

  1. Supp DM, Hahn JM, McFarland KL, Combs KA, Lee KSS, Inceoglu B, Wan D, Boyce ST, Hammock BD: Soluble epoxide hydrolase inhibition and topical epoxyeicosatrienoic acid treatment improve vascularization of engineered skin substitutes after transplantation to mice. PRS Global Open 2016; In Press: accepted 10/4/2016.
  2. Hahn JM, McFarland KL, Combs AK, Supp DM: Partial epithelial-mesenchymal transition in keloid scars: regulation of keloid keratinocyte gene expression by transforming growth factor-β1. Burns & Trauma 2016; 4:30.
  3. Boyce ST, and Supp DM: Biologic Skin Substitutes. In: Skin Tissue Engineering and Regenerative Medicine, Holmes JH and Albanna MZ, Eds. Elsevier, Inc., Waltham, MA.
  4. Kim JY, Willard JJ, Supp DM, Roy S, Gordillo GM, Sen CK, Powell HM. Burn scar biomechanics following pressure garment therapy. Plast Reconstruct Surg, 2015; 136(3):572-581.
  5. Boyce S, Zimmerman R, Supp D: Tumorigenicity testing in athymic mice of cultured human melanocytes for transplantation in engineered skin substitutes. Cell Transplantation 2015; 24(8):1423-1429.
  6. Alexander JW, Supp DM: Role of arginine and omega-3 fatty acids in wound healing and infection. Adv Wound Care 2014;3(11):682-690.
  7. Supp DM, Hahn JM, McFarland KL, Glaser K: Inhibition of hyaluronan synthase 2 (HAS2) reduces the abnormal migration rate of keloid keratinocytes. J Burn Care Res 2014; 35(1):84-92.
  8. Osterburg AR, Hexley P, Supp DM, Robinson CT, Noel G, Ogle C, Boyce ST, Aronow BJ, Babcock GF: Concerns over interspecies transcriptional comparisons in mice and humans after trauma. Proc Natl Acad Sci USA 2013; 110(36):E3370.
  9. Sriwiriyanont P, Lynch K, McFarland KL, Supp D, Boyce S: Characterization of chimeric hair follicle development in human engineered skin substitutes. PLOS One 2013; 8(6):e65664.
  10. Hahn JM, Glaser K, McFarland KL, Aronow BJ, Boyce ST, and Supp DM: Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology. Wound Rep Regen 2013; 21:530-544.
  11. Sriwiriyanont P, Lynch K, Maier E, Hahn J, Supp D, Boyce S: Morphogenesis of chimeric hair follicles in engineered skin substitutes with human keratinocytes and murine dermal papilla cells. Exp Dermatol 2012; 21(10):783-5.
  12. Swope V, Jameson J, McFarland K, Supp D, Miller W, McGraw D, Patel MA, Nix MA, Milhauser G, Babcock G, Abdel-Malek ZA: Defining MC1R Regulation in human melanocytes by its agonist α-melanocortin and antagonists agouti signaling protein and β-defensin 3. J Invest Dermatol 2012; 132(9):2255-62.
  13. Boyce ST, Rice RK, Lynch KA, Supp AP, Swope VB, Kagan RJ, and Supp DM: Assessment of replication rates of human keratinocytes in engineered skin substitutes grafted to athymic mice. Wound Rep Regen 2012; 20(4):544-51.
  14. Supp DM, Hahn JM, Glaser K, McFarland KL, Boyce ST: Deep and superficial keloid fibroblasts contribute differentially to tissue phenotype in a novel in vivo model of keloid scar. Plast Reconstruct Surg 2012; 129(6):1259-1271.
  15. Supp DM: Genomic reprogramming and skin-like maturation of engineered human skin substitutes. Adv Wound Care 2012; 1(2):63-68.
  16. Supp DM, Glaser K, Hahn JM, McFarland KL, Boyce ST: Abnormal responses of keloid tissue to wounding identified using in vitro model system. ePlasty 2012; e19.

Grants: current (PI)

Epoxyeicosatrienoic Acids: Therapeutic Potential in Skin Grafting and Burns

Shriners Hospitals for Children #85800

Period of Support: 1/1/17-12/31/20

Targeting Hyaluronic Acid Synthesis to Suppress Abnormal Scarring

Shriners Hospitals for Children #85500

Period of Support: 1/1/15-12/31/19

Contact

Dorothy M. Supp, Ph.D.
Senior Investigator
Research
[email protected]

Translate »